Topic: Primary Care, Cardiovascular disease
Conditions
Interventions
Timing of medication switch: Subjects already taking hypertensive medication in usual care will be identified from collaborating practices and within secondary care clinics. Subjects will be invited t
Sponsors
NHS Tayside (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both diagnosed and treated for hypertension (all forms) with at least one antihypertensive drug 2. Aged above 18 years 3. Have a valid email address
Exclusion criteria
Exclusion criteria: 1. Subjects who take twice daily antihypertensive therapy. 2. Subjects who work shift patterns that include a night shift. 3. Subjects who unwilling to consent to: 3.1. Follow up 3.2. Provide a surrogate to be contacted and/or 3.3. Give consent for their family practice to release follow up clinical data 3.4. To have their physical case records abstracted if required 3.5. To have their electronic case records searched and abstracted if required 3.6. To allow their consent from to be copied to authorities from whom the study team is requesting medical data 4. Those participating in another clinical trial or who have done in the last 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Anti Platelet Trialists' Collaboration: composite endpoint of non-fatal myocardial infarction, non-fatal stroke or vascular death. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Each component of the primary endpoint 2. Hospitalisation for non-fatal stroke 3. Hospitalisation for non-fatal MI 4. Vascular death 5. All-cause mortality 6. Hospitalisation or death from congestive heart failure. 1. Adherence to the evening dosing regimen vs morning (patient reported) with particular reference to patients taking diuretic therapy. 2. Patient reported and hospitalised adverse events in the morning versus evening groups will be compared. In particular falls and fractures will be recorded. 3. Home BP readings taken by a subset of patients will be compared between morning & evening dosing. 4. An additional proposed substudy is a telephone administered cognitive function assessment to compare patients on morning and evening dosing. | — |
Countries
Scotland, United Kingdom
Outcome results
None listed